Gabriele Elser

Wiesbaden, HE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Treatment and outcome of elderly patients with presumed early ovarian cancer in Germany: real-world observations from the quality-assurance program of the AGO Study Group.

Treatment and outcome of elderly patients with presumed early ovarian cancer in Germany: real-world observations from the quality-assurance program of the AGO Study Group.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: May 13, 2026

Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.

Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study: A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus.

Journal: Geburtshilfe und Frauenheilkunde
Published: December 19, 2024

Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observations.

Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group - Real-world observations.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: December 03, 2024

Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group.

Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: March 31, 2023

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).

Journal: PloS one
Published: June 09, 2017

Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.

Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.

Journal: BMC medical ethics
Published: January 15, 2016

Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials.

Roadmap for the European Network of Gynaecological Trial groups (ENGOT) Trials.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: August 24, 2013

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).

Journal: Investigational new drugs
Published: July 24, 2013
Showing 1-8 of 8

Last Updated: 09/26/2026